Recruiting PHASE1 INTERVENTIONAL 3-arm NCT06789159

A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)

Sponsor: National Cancer Institute (NCI)

Conditions Diffuse Large B Cell Lymphoma Refractory Diffuse Large B Cell Lymphoma Relapsed Epstein-Barr Virus (EBV) Infection

Interventions VK-2019

Updated 4 times since 2025 Last updated: Oct 16, 2025 Started: May 22, 2025 Primary completion: Oct 1, 2028 Completion: Oct 1, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Diffuse Large B Cell Lymphoma Refractory and Diffuse Large B Cell Lymphoma Relapsed and is currently actively recruiting participants. National Cancer Institute (NCI) leads this study, which shows 4 recorded versions since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Nov 2025 — Present [monthly]

Recruiting PHASE1
Jul 2025 — Nov 2025 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Jun 2025 — Jul 2025 [monthly]

Not Yet Recruiting PHASE1
Feb 2025 — Jun 2025 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)
The Wistar Institute
Thomas Jefferson University

Data source: Thomas Jefferson University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Philadelphia, United States